NASDAQ:LOXO - Loxo Oncology Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$234.66 0.00 (0.00 %)
(As of 02/18/2019 08:19 AM ET)
Previous Close$234.66
Today's Range$234.66 - $234.66
52-Week Range$101.70 - $234.93
Volume400 shs
Average Volume727,427 shs
Market Capitalization$7.18 billion
P/E Ratio-44.19
Dividend YieldN/A
Beta2.51
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Receive LOXO News and Ratings via Email

Sign-up to receive the latest news and ratings for LOXO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOXO
CUSIPN/A
Phone203-653-3880

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.30 million
Book Value$12.63 per share

Profitability

Net Income$-148,870,000.00

Miscellaneous

Employees59
Market Cap$7.18 billion
OptionableOptionable

Loxo Oncology (NASDAQ:LOXO) Frequently Asked Questions

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) issued its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.15. The biopharmaceutical company earned $42.60 million during the quarter, compared to analyst estimates of $32.36 million. Loxo Oncology had a negative net margin of 43.49% and a negative return on equity of 16.42%. During the same period last year, the business posted ($0.94) earnings per share. View Loxo Oncology's Earnings History.

When is Loxo Oncology's next earnings date?

Loxo Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Loxo Oncology.

What price target have analysts set for LOXO?

15 brokers have issued 12 month target prices for Loxo Oncology's shares. Their predictions range from $132.00 to $235.00. On average, they expect Loxo Oncology's stock price to reach $193.0909 in the next twelve months. This suggests that the stock has a possible downside of 17.7%. View Analyst Price Targets for Loxo Oncology.

What is the consensus analysts' recommendation for Loxo Oncology?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Loxo Oncology in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Loxo Oncology.

What are Wall Street analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:
  • 1. JMP Securities analysts commented, "We view the success of larotrectinib as a crucial step in the paradigm shift we see occurring in the treatment landscape for oncology toward biomarker-driven drug development. Further, we consider the FDA’s support of larotrectinib, which has benefited from expedited development in the U.S. due to its breakthrough therapy status and accelerated approval pathways, as signaling the agency’s commitment to ushering in a new era of targeted medicines in oncology." (11/29/2018)
  • 2. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (11/16/2018)
  • 3. Citigroup Inc analysts commented, "Enbrel treats rheumatoid arthritis and related diseases and is a major contributor to Amgen’s sales and growth. We currently estimate that Enbrel sales in the psoriatic arthritis (PsA) setting account for 13% of total Enbrel sales in 2018. Enbrel’s overall market penetration likely will moderate due to completion from biosimilars outside the US and potentially in the US. We anticipate Enbrel sales to decline by approximately 6% per year from 2017-2022, but will still account for 12% of sales by 2022. However, these data presented today at ACR in PA could lead to increased adoption in the setting and provide upside to our outlook." (10/24/2018)

Has Loxo Oncology been receiving favorable news coverage?

Media headlines about LOXO stock have been trending neutral on Monday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Loxo Oncology earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Are investors shorting Loxo Oncology?

Loxo Oncology saw a decrease in short interest in January. As of January 15th, there was short interest totalling 1,057,346 shares, a decrease of 54.1% from the December 31st total of 2,305,647 shares. Based on an average trading volume of 3,279,694 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.9% of the shares of the company are short sold. View Loxo Oncology's Current Options Chain.

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:
  • Dr. Joshua H. Bilenker, Founder, Pres, CEO & Director (Age 47)
  • Ms. Jennifer Burstein M.B.A. CPA, Sr. VP of Fin. (Age 47)
  • Mr. Jacob S. Van Naarden, Chief Operating Officer (Age 34)
  • Ms. Jennifer L. Kronick, VP of HR
  • Dr. Nisha Nanda, Chief Devel. Officer (Age 44)

Who are Loxo Oncology's major shareholders?

Loxo Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.45%), Eagle Asset Management Inc. (1.21%), Polar Capital LLP (1.16%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.08%) and venBio Select Advisor LLC (1.06%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty, Lori Anne Kunkel, Naarden Jacob Van, Orbimed Advisors Llc and Timothy M Mayleben. View Institutional Ownership Trends for Loxo Oncology.

Which major investors are selling Loxo Oncology stock?

LOXO stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Polar Capital LLP, Victory Capital Management Inc., First Quadrant L P CA, Rhenman & Partners Asset Management AB, KBC Group NV, Dimensional Fund Advisors LP and Frontier Capital Management Co. LLC. Company insiders that have sold Loxo Oncology company stock in the last year include Aisling Capital Iii Lp, Jennifer Burstein, Joshua H Bilenker, Lori Anne Kunkel, Naarden Jacob Van and Timothy M Mayleben. View Insider Buying and Selling for Loxo Oncology.

Which major investors are buying Loxo Oncology stock?

LOXO stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Millennium Management LLC, Fiera Capital Corp, Hillhouse Capital Advisors Ltd., Eaton Vance Management, Candriam Luxembourg S.C.A., Brown Advisory Inc. and Emerald Advisers LLC. View Insider Buying and Selling for Loxo Oncology.

How do I buy shares of Loxo Oncology?

Shares of LOXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of LOXO stock can currently be purchased for approximately $234.66.

How big of a company is Loxo Oncology?

Loxo Oncology has a market capitalization of $7.18 billion and generates $21.30 million in revenue each year. The biopharmaceutical company earns $-148,870,000.00 in net income (profit) each year or ($5.31) on an earnings per share basis. Loxo Oncology employs 59 workers across the globe.

What is Loxo Oncology's official website?

The official website for Loxo Oncology is http://www.loxooncology.com.

How can I contact Loxo Oncology?

Loxo Oncology's mailing address is 281 TRESSER BOULEVARD 9TH FLOOR, STAMFORD CT, 06901. The biopharmaceutical company can be reached via phone at 203-653-3880 or via email at [email protected]


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe LOXO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOXO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel